VB10.16
- Generic Name
- VB10.16
- Drug Type
- Biotech
- Background
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
- Conditions
- HPV-Related MalignancyCervical CancerHPV-Related Cervical Carcinoma
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 130
- Registration Number
- NCT06099418
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
- Conditions
- HPV Positive Oropharyngeal Squamous Cell CarcinomaHNSCC
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 51
- Registration Number
- NCT06016920
- Locations
- 🇫🇷
CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM), Montpellier, France
🇨🇿Fakultni nemocnice Olomouc, Olomuoc, Olomouc, Czechia
🇫🇷Hospices Civils De Lyon, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.